Full Press Release Details
Kamada Files Annual Report for the Year Ended
REHOVOT, Israel, and Hoboken, NJ - March
15, 2023 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed
products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it has filed
its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC").
The annual report, including the Company's
audited consolidated financial statements, can be accessed via the SEC's website at https://www.sec.gov/edgar.shtml, as well as
under the SEC Filings section on Kamada's investor relations website at https://www.kamada.com/.
The Company will deliver a hard copy of its annual
report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be
directed to Kamada's Investor Relations Department at IR@kamada.com.
Kamada Ltd. (the "Company") is a commercial
stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in
the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative
development pipeline targeting areas of significant unmet medical need. The Company's strategy is focused on driving profitable
growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical
fields. The Company's commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: CYTOGAM ,
KEDRAB , WINRHO SDF , VARIZIG , HEPAGAM B and GLASSIA , as well as KAMRAB , KAMRHO (D) and two types of
equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic
partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India,
Australia and other countries in Latin America, Europe, Middle East, and Asia. The Company leverages its expertise and presence in the
Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers
and during recent years added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European Medicines
Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA
registered plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the
manufacture of KAMRHO (D). In addition to the Company's commercial operation, it invests in research and development of new product
candidates. The Company's leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is
continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity
Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of
the outstanding ordinary shares.
Chief Financial Officer
LifeSci Advisors, LLC